New drug trial targets uncontrollable hunger in rare genetic disorder
NCT ID NCT07266324
Summary
This study is testing whether a new oral medication called BMB-101 can safely reduce the severe, constant hunger experienced by adults with Prader-Willi Syndrome (PWS). Sixteen participants will be randomly assigned to receive either the real drug or a placebo for 16 weeks, followed by an option to continue taking the drug. The main goal is to see if the drug lowers scores on a questionnaire that measures the intensity of hunger and food-seeking behaviors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.